Cue Biopharma, Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
Cue Biopharma, Inc. (CUE) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2020-03-12
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-12-31 was $0.00.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-09-30 was $0.00.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-06-30 was $0.00.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2019-03-31 was $0.00.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2019 was $0.00.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2018 was $0.00.
- Cue Biopharma, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2017 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month |
|---|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | -$20.00K 10-Q · filed 2018-11-13 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | -$20.00K 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 | |||||
| 2017-12-31 | $0.00 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |